1. Systemic increase in IL-26 is associated with severe COVID-19 and comorbid obstructive lung disease.
- Author
-
Cardenas EI, Robertson J, Misaghian S, Brown J, Wang M, Stengelin M, Sigal G, Wohlstadter J, Gisslén M, and Lindén A
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Adult, Severity of Illness Index, Pulmonary Disease, Chronic Obstructive immunology, Pulmonary Disease, Chronic Obstructive blood, Viral Load, Biomarkers blood, Spike Glycoprotein, Coronavirus immunology, COVID-19 immunology, COVID-19 blood, SARS-CoV-2 immunology, Interleukins blood, Comorbidity
- Abstract
Background: IL-26 is a key mediator of pulmonary host defense given its abundant expression in human airways and its established antibacterial properties. Moreover, recent studies indicate that IL-26 can also inhibit viral replication. Along these lines, we have previously reported an increase in the plasma concentration of IL-26 among patients with acute COVID-19 that is linked to harmful hyperinflammation. Nevertheless, it is still unclear whether this systemic increase in IL-26 relates to disease severity, sex, comorbidities, viral load, or the innate immune response in acute COVID-19., Methods: IL-26 was quantified using ELISA in plasma samples from a large cohort of well-characterized patients with acute COVID-19 (n=178) and healthy controls (n=30). The plasma concentrations of SARS-CoV-2 nucleocapsid and spike protein, as well as those of IFN-α2a, IFN-β, and IFN-γ, were determined using electrochemiluminescence immunoassay. The concentration of double-stranded DNA was determined using fluorometry., Results: The plasma concentration of IL-26 was increased in patients with severe/critical COVID-19, particularly among males and patients with comorbid obstructive lung disease. Moreover, the concentration of IL-26 displayed positive correlations with length of hospital stay, as well as with systemic markers of viral load, antiviral immunity, and extracellular DNA., Conclusions: Systemic IL-26 is involved in severe COVID-19, especially in males and patients with comorbid obstructive lung disease. These findings argue that systemic IL-26 has pathogenic and antiviral relevance, as well as biomarker potential., Competing Interests: Authors SM, JB, MW, MS, GS, and JW are employed by Meso Scale Diagnostics, LLC., Rockville, MD, USA. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Cardenas, Robertson, Misaghian, Brown, Wang, Stengelin, Sigal, Wohlstadter, Gisslén and Lindén.)
- Published
- 2024
- Full Text
- View/download PDF